Effects of propiony-Ll--carnitine on cardiac dysfunction in streptozotocin-diabetic rats

European Journal of Pharmacology

Volumn 357, Issue 2-3, 1998, Pages 185-191

  Terada, Ryuya ^a   Matsubara, Tatsuaki ^a   Koh, Naoki ^a   Nakamura, Jiro ^a   Hotta, Nigishi ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiac function; Lipid metabolism; Propionyl L carnitine; Rat; Streptozotocin induced diabetes

Indexed keywords

CARNITINE; PROPIONYLCARNITINE; CARDIOTONIC AGENT; DRUG DERIVATIVE; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFECT; HEART FUNCTION; LIPID BLOOD LEVEL; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; ANIMAL; BLOOD; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEART; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METABOLISM; PATHOPHYSIOLOGY; PERFUSION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CARDIOTONIC AGENTS; CARNITINE; DIABETES MELLITUS, EXPERIMENTAL; HEART; LIPIDS; MALE; MYOCARDIUM; PERFUSION; RATS; RATS, WISTAR; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0032544229     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00539-1     Document Type: Article

References (41)

1. Bhimji S., Godin D.V., McNeill J.H. Biochemical and functional changes in hearts from rabbits with diabetes. Diabetologia. 28:1985;452-457.
2. Broderick T.L., Haloftis G., Paulson D.J. L-Propionylcarnitine enhancement of substrate oxidation and mitochondrial respiration in the diabetic rat heart. J. Mol. Cell. Cardiol. 28:1996;331-340.
3. Corr P.B., Gross R.W., Sobel B.E. Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ. Res. 55:1984;135-154.
4. Fein F.S., Kornstein L.B., Strobeck J.E., Capasso J.M., Sonnenblick E.H. Altered myocardial mechanics in diabetic rats. Circ. Res. 47:1980;922-933.
5. Ferrari R., Dilisa F., Willem J.d.J., Ceconi C., Pasini E., Barbato R., Menabò R., Barbieri M., Cerbai E., Mugelli A. Prolonged propionyl-L-carnitine pre-treatment of rabbit: biochemical, hemodynamic and electrophysiological effects on myocardium. J. Mol. Cell. Cardiol. 24:1992;219-232.
6. Garland P.B., Randle P.J. Regulation of glucose uptake by muscle: 10. Effects of alloxan-diabetes, starvation, hypophysectomy and adrenalectomy, and of fatty acids, ketone bodies and pyruvate, on the glycerol output and concentrations of free fatty acids, long-chain fatty acyl-coenzyme A, glycerol phosphate and citrate-cycle intermediates in rat heart and diaphragm muscles. Biochem. J. 93:1964;678-687.
7. Goa K.L., Brogden R.N. L-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs. 34:1987;1-24.
8. Hamby R.I., Zoneraich S., Sherman L. Diabetic cardiomyopathy. J. Am. Med. Assoc. 229:1974;1749-1754.
9. Hotta N., Koh N., Sakakibara F., Nakamura J., Hamada Y., Hara T., Fukasawa H., Kakuta H., Sakamoto N. Effect of propionyl-L-carnitine on oscillatory potentials in electroretinogram in streptozotocin-diabetic rats. Eur. J. Pharmacol. 311:1996;199-206.
10. Hotta N., Koh N., Sakakibara F., Nakamura J., Hamada Y., Hara T., Nakashima E., Sasaki H., Fukasawa H., Kakuta H., Sakamoto N. Effects of propionyl-L-carnitine and insulin on the electroretinogram, nerve conduction and nerve blood flow in rats with streptozotocin-induced diabetes. Pflüg. Arch. Eur. J. Physiol. 431:1996;564-570.
11. Hotta N., Koh N., Sakakibara F., Nakamura J., Hamada Y., Wakao T., Hara T., Mori K., Naruse K., Nakashima E., Sakamoto N. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor. J. Pharmacol. Exp. Ther. 276:1996;49-55.
12. Hülsmann W.C. Biochemical profile of propionyl-L-carnitine. Cardiovasc. Drugs Ther. 5:1991;7-10.
13. Ido Y., McHowat J., Chang K.C., Arrigoni-Martelli E., Orfalian Z., Kilo C., Corr P.B., Williamson J.R. Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine. Diabetes. 43:1994;1469-1477.
14. Kannel W.B., Hjortland W., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am. J. Cardiol. 34:1974;29-34.
15. Litwin S.E., Raya T.E., Anderson P.G., Daugherty S., Goldman S. Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle. J. Clin. Invest. 86:1990;481-488.
16. McGarry J.D., Foster D.W. An improved and simplified radioisotopic assay for determination of free and esterified carnitine. J. Lipid Res. 17:1976;277-281.
17. Neely J.R., Liebermeister H., Battersby E.J., Morgan H.E. Effect of pressure development on oxygen consumption by isolated rat heart. Am. J. Physiol. 212:1967;804-814.
18. Nonoda K., Matsubara T., Kanashiro M., Suzuki O., Nakao M., Sakamoto N. Effects of diabetes on lipid peroxidation and scavenger activity in ischemia/reperfusion injury. Jpn. Heart J. 34:1993;591-599.
19. Packer L., Valenza M., Serbinova E., Starke-Reed P., Frost K., Kagan V. Free radical scavenging is involved in the protective effect of propionyl-L-carnitine against ischemia-reperfusion injury of the heart. Arch. Biochem. Biophys. 288:1991;533-537.
20. Pasini E., De Giuli F., Comini L., Menotti A., Ferrari R., Dhalla N.S. Effect of propionyl-L-carnitine on experimental induced cardiomyopathy in rats. Am. J. Cardiovasc. Pathol. 4:1992;216-222.
21. Paulson D.J., Schmidt M.J., Romens J., Shug A.L. Metabolic and physiological differences between zero-flow and low-flow myocardial ischemia: effects of L-acetylcarnitine. Basic Res. Cardiol. 79:1984;551-561.
22. Paulson D.J., Schmidt M.J., Traxler J.S., Ramacci M.T., Shug A.L. Improvement of myocardial function in diabetic rats after treatment with L-carnitine. Metabolism. 33:1984;358-363.
23. Penpargkul S., Schaible T., Yipintsoi T., Scheuer J. The effect of diabetes on performance and metabolism of rat hearts. Circ. Res. 47:1980;911-921.
24. Regan T.J., Lyons M.M., Ahmed S.S., Levinson G.E., Oldewurtel H.A., Ahmad M.R., Haider B. Evidence for cardiomyopathy in familial diabetes mellitus. J. Clin. Invest. 60:1977;885-899.
25. Reibel D.K., Uboh C.E., Kent R.L. Altered coenzyme A and carnitine metabolism in pressure-overload hypertrophied hearts. Am. J. Physiol. 244:1983;H839-H843.
26. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., Olsen E., Thiene G., Goodwin J., Gyarfas I., Martin I., Nordet P. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 93:1996;841-842.
27. Rodrigues B., Xiang H., McNeill J.H. Effect of L-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes. 37:1988;1358-1364.
28. Rodrigues B., Seccombe D., McNeill J.H. Lack of effect of oral L-carnitine treatment on lipid metabolism and cardiac function in chronically diabetic rats. Can. J. Physiol. Pharmacol. 68:1990;1601-1608.
29. Rösen P., Windeck P., Zimmer H.G., Frenzel H., Bürrig K.F., Rainauer H. Myocardial performance and metabolism in non-ketotic, diabetic rat hearts: myocardial function and metabolism in vivo and in the isolated perfused heart under the influence of insulin and octanoate. Basic Res. Cardiol. 81:1986;620-635.
30. Rubler S., Sajadi M.R.M., Araoye M.A., Holford F.D. Noninvasive estimation of myocardial performance in patients with diabetes. Effect of alcohol administration. Diabetes. 27:1978;127-134.
31. Sunni S., Bishop S.P., Kent S.P., Geer J.C. Diabetic cardiomyopathy. A morphological study of intramyocardial arteries. Arch. Pathol. Lab. Med. 110:1986;375-381.
32. Suzuki O., Matsubara T., Kanashiro M., Nakao M., Terada R., Nishimura H., Haruta K., Ikeda T., Sakamoto N. Are diabetic hearts more resistant to ischemia/reperfusion injury? Jpn. Circ. J. 57:1993;328-334.
33. Tahiliani A.G., McNeill J.H. Diabetes-induced abnormalities in the myocardium. Life Sci. 38:1986;959-974.
34. Tilton R.G., Chang K., Pugliese G., Eades D.M., Province M.A., Sherman W.R., Kilo C., Williamson J.R. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes. 38:1989;1258-1270.
35. Tripp M.E., Katcher M.L., Peters H.A., Gilbert E.F., Arya S., Hodach R.J., Shug A.L. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis. A treatable cardiomyopathy. N. Engl. J. Med. 305:1981;385-390.
36. Vary T.C., Neely J.R. A mechanism for reduced myocardial carnitine levels in diabetic animals. Am. J. Physiol. 243:1982;H154-H158.
37. Whitmer J.T. L-Carnitine treatment improves cardiac performance and restores high-energy phosphate pools in cardiomyopathic Syrian hamster. Circ. Res. 61:1987;396-408.
38. Williamson J.R., Chang K., Frangos M., Hasan K.S., Ido Y., Kawamura T., Nyengaard J.R., Van den Enden M., Kilo C., Tilton R.G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 42:1993;801-813.
39. Wittels B., Bressler R. Biochemical lesion of diphtheria toxin in the heart. J. Clin. Invest. 43:1964;630-637.
40. York C.M., Cantrell C.R., Borum P.R. Cardiac carnitine deficiency and altered carnitine transport in cardiomyopathic hamsters. Arch. Biochem. Biophys. 221:1983;526-533.
41. Zonszein, J., Sonnenblick, E.H., 1998. Endocrine diseases and the cardiovascular system. In: Alexander, R.W., Schlant, R.C., Fuster, V. (Eds.), The Heart, 9th edn. McGraw-Hill, New York, NY, pp. 2117-2142.